{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sulfasalazine", "query": { "intervention": "sulfasalazine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sulfasalazine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T09:35:12.225Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00579878", "title": "Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate-Sulfasalazine-Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide-Sulfasalazine-Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "19 Years to 80 Years" }, "enrollment_count": 69, "start_date": "2001-03-27", "completion_date": "2010-03-11", "has_results": true, "last_update_posted_date": "2023-10-02", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579878" }, { "nct_id": "NCT04725422", "title": "CHronic Nonbacterial Osteomyelitis International Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Nonbacterial Osteomyelitis", "Chronic Recurrent Multifocal Osteomyelitis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Pamidronate", "type": "DRUG" }, { "name": "Zoledronic acid", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "NSAID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 2000, "start_date": "2018-08-01", "completion_date": "2050-08", "has_results": false, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04725422" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-12-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT05782335", "title": "Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [], "intervention_types": [], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-11-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05782335" }, { "nct_id": "NCT02434861", "title": "An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chemotherapy-induced Nausea and Vomiting" ], "interventions": [ { "name": "Rolapitant", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Cooperstown Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 102, "start_date": "2015-05", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02434861" }, { "nct_id": "NCT00531817", "title": "A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Permitted DMARDs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 619, "start_date": "2007-10", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-08-20", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 156, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Lake Havasu City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00531817" }, { "nct_id": "NCT03847311", "title": "Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Chronic Pain Due to Malignancy (Finding)" ], "interventions": [ { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "94 Years", "sex": "FEMALE", "summary": "18 Years to 94 Years · Female only" }, "enrollment_count": 7, "start_date": "2021-05-03", "completion_date": "2023-10-09", "has_results": true, "last_update_posted_date": "2025-01-09", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 2, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03847311" }, { "nct_id": "NCT00062465", "title": "Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "TwHF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 157, "start_date": "2003-06", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062465" }, { "nct_id": "NCT05445440", "title": "A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "BMS-986371", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "18 Years to 50 Years · Male only" }, "enrollment_count": 30, "start_date": "2022-09-06", "completion_date": "2022-11-23", "has_results": false, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05445440" }, { "nct_id": "NCT02374021", "title": "Treatments Against RA and Effect on FDG-PET/CT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 159, "start_date": "2016-07", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2022-10-26", "last_synced_at": "2026-09-14T09:35:12.225Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Murrieta", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02374021" } ] }